Ipilimumab blocks the effect of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), thereby enhancing the signaling between antigen-presenting cells and activated T-cells via the CD28 receptor on T-cells.
More to come later on your other questions.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”